Datapoint: J&J’s Rybrevant Approved in NSCLC

Following a priority review, the FDA on May 21 approved Johnson & Johnson’s Rybrevant for the treatment of non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) Exon 20 Insertion mutations whose disease has continued to progress following chemotherapy. The bispecific antibody is the first drug to receive this indication. Under the pharmacy benefit, among the most advantaged NSCLC (with EFGR mutations) drugs are Genentech’s Tarceva, which holds covered or better status for 73% of all insured lives, and Boehringer Ingelheim’s Gilotrif, which holds covered or better status for 71% of lives.

SOURCE: MMIT Analytics, as of 5/24/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 5

Datapoint: North Carolina Delays Launch of New Medicaid MCOs

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 4

Datapoint: FDA Approves Avastin Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 3

Datapoint: AstraZeneca, Merck Pull Lynparza in Ovarian Cancer

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today